End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.54 CNY | -0.81% | -3.28% | -16.44% |
04-25 | Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-28 | Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023 | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.44% | 1.97B | D+ | ||
+1.85% | 95.18B | A- | ||
-4.34% | 37.55B | A- | ||
+75.79% | 28.2B | A | ||
-14.61% | 15.63B | C | ||
-3.46% | 13.63B | B- | ||
-12.31% | 11.5B | D+ | ||
+184.77% | 10.81B | D | ||
-54.13% | 9.23B | B | ||
+6.22% | 9.09B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300009 Stock
- Ratings Anhui Anke Biotechnology (Group) Co., Ltd.